Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 371

1.

Cefepime neurotoxicity: thresholds and risk factors. A retrospective cohort study.

Boschung-Pasquier L, Atkinson A, Kastner LK, Banholzer S, Haschke M, Buetti N, Furrer DI, Hauser C, Jent P, Que YA, Furrer H, Babouee Flury B.

Clin Microbiol Infect. 2019 Jul 5. pii: S1198-743X(19)30379-9. doi: 10.1016/j.cmi.2019.06.028. [Epub ahead of print]

2.

Gradual in vitro Evolution of Cefepime Resistance in an ST131 Escherichia coli Strain Expressing a Plasmid-Encoded CMY-2 β-Lactamase.

Donà V, Scheidegger M, Pires J, Furrer H, Atkinson A, Babouee Flury B.

Front Microbiol. 2019 Jun 12;10:1311. doi: 10.3389/fmicb.2019.01311. eCollection 2019.

3.

IL-4 polymorphism influences susceptibility to Pneumocystis jirovecii pneumonia in HIV-positive patients.

Wójtowicz A, Bibert S, Taffé P, Bernasconi E, Furrer H, Günthard HF, Hoffmann M, Osthoff M, Cavassini M, Bochud PY; Swiss HIV Cohort Study.

AIDS. 2019 Sep 1;33(11):1719-1727. doi: 10.1097/QAD.0000000000002283.

4.

Why do sub-Saharan Africans present late for HIV care in Switzerland?

Hachfeld A, Darling K, Calmy A, Ledergerber B, Weber R, Battegay M, Wissel K, Di Benedetto C, Fux CA, Tarr PE, Kouyos R, Ruggia LS, Furrer HJ, Wandeler G; Swiss HIV Cohort Study.

HIV Med. 2019 Jul;20(6):418-423. doi: 10.1111/hiv.12727. Epub 2019 May 6.

PMID:
31062497
5.

Contribution of genetic background and clinical D:A:D risk score to chronic kidney disease in Swiss HIV-positive persons with normal baseline estimated glomerular filtration rate.

Dietrich LG, Barceló C, Thorball CW, Ryom L, Burkhalter F, Hasse B, Furrer H, Weisser M, Steffen A, Bernasconi E, Cavassini M, de Seigneux S, Csajka C, Fellay J, Ledergerber B, Tarr PE; Swiss HIV CohortS Study.

Clin Infect Dis. 2019 Apr 6. pii: ciz280. doi: 10.1093/cid/ciz280. [Epub ahead of print]

PMID:
30953057
6.

Emulating a trial of joint dynamic strategies: An application to monitoring and treatment of HIV-positive individuals.

Caniglia EC, Robins JM, Cain LE, Sabin C, Logan R, Abgrall S, Mugavero MJ, Hernández-Díaz S, Meyer L, Seng R, Drozd DR, Seage Iii GR, Bonnet F, Le Marec F, Moore RD, Reiss P, van Sighem A, Mathews WC, Jarrín I, Alejos B, Deeks SG, Muga R, Boswell SL, Ferrer E, Eron JJ, Gill J, Pacheco A, Grinsztejn B, Napravnik S, Jose S, Phillips A, Justice A, Tate J, Bucher HC, Egger M, Furrer H, Miro JM, Casabona J, Porter K, Touloumi G, Crane H, Costagliola D, Saag M, Hernán MA.

Stat Med. 2019 Jun 15;38(13):2428-2446. doi: 10.1002/sim.8120. Epub 2019 Mar 18.

PMID:
30883859
7.

Emergence of drug resistance in the Swiss HIV Cohort Study under potent antiretroviral therapy is observed in socially disadvantaged patients.

Abela IA, Scherrer AU, Böni J, Yerly S, Klimkait T, Perreau M, Hirsch HH, Furrer H, Calmy A, Schmid P, Cavassini M, Bernasconi E, Günthard HF; Swiss HIV Cohort Study.

Clin Infect Dis. 2019 Mar 7. pii: ciz178. doi: 10.1093/cid/ciz178. [Epub ahead of print]

PMID:
30843028
8.

Risk Factors for Low CD4+ Count Recovery Despite Viral Suppression Among Participants Initiating Antiretroviral Treatment With CD4+ Counts > 500 Cells/mm3: Findings From the Strategic Timing of AntiRetroviral Therapy (START) Trial.

Boatman JA, Baker JV, Emery S, Furrer H, Mushatt DM, Sedláček D, Lundgren JD, Neaton JD; INSIGHT START Study Group.

J Acquir Immune Defic Syndr. 2019 May 1;81(1):10-17. doi: 10.1097/QAI.0000000000001967.

PMID:
30664075
9.

Laboratory-Reflex Cryptococcal Antigen Screening Is Associated With a Survival Benefit in Tanzania.

Faini D, Kalinjuma AV, Katende A, Mbwaji G, Mnzava D, Nyuri A, Glass TR, Furrer H, Hatz C, Boulware DR, Letang E.

J Acquir Immune Defic Syndr. 2019 Feb 1;80(2):205-213. doi: 10.1097/QAI.0000000000001899.

10.

Fatal Measles Virus Infection After Rituximab-Containing Chemotherapy in a Previously Vaccinated Patient.

Jent P, Trippel M, Frey M, Pöllinger A, Berezowska S, Langer R, Furrer H, Béguelin C.

Open Forum Infect Dis. 2018 Nov 1;5(11):ofy244. doi: 10.1093/ofid/ofy244. eCollection 2018 Nov.

11.

Interferon lambda 3/4 polymorphisms are associated with AIDS-related Kaposi's sarcoma.

Bibert S, Wójtowicz A, Taffé P, Tarr PE, Bernasconi E, Furrer H, Günthard HF, Hoffmann M, Kaiser L, Osthoff M, Fellay J, Cavassini M, Bochud PY; Swiss HIV Cohort Study.

AIDS. 2018 Nov 28;32(18):2759-2765. doi: 10.1097/QAD.0000000000002004.

PMID:
30234607
12.

Prevalence and Evolution of Renal Impairment in People Living With HIV in Rural Tanzania.

Mapesi H, Kalinjuma AV, Ngerecha A, Franzeck F, Hatz C, Tanner M, Mayr M, Furrer H, Battegay M, Letang E, Weisser M, Glass TR; KIULARCO Study Group .

Open Forum Infect Dis. 2018 Apr 6;5(4):ofy072. doi: 10.1093/ofid/ofy072. eCollection 2018 Apr.

13.

Rapid decline of anti-hepatitis C virus (HCV) antibodies following early treatment of incident HCV infections in HIV-infected men who have sex with men.

Aebi-Popp K, Wandeler G, Salazar-Vizcaya L, Metzner K, Stöckle M, Cavassini M, Hoffmann M, Lüthi A, Suter F, Bernasconi E, Fehr J, Furrer H, Rauch A; the Swiss HIV Cohort Study.

HIV Med. 2018 Jul;19(6):420-425. doi: 10.1111/hiv.12602. Epub 2018 Mar 24.

PMID:
29573533
14.

Fewer pills do not mean fewer drug-drug interactions: severe rhabdomyolysis on Elvitegravir/Cobicistat and statin treatment.

Perrone C, Rauch A, Furrer H, Hug M, Wandeler G.

AIDS. 2018 Mar 13;32(5):676-678. doi: 10.1097/QAD.0000000000001746. No abstract available.

PMID:
29494427
15.

Intestinal colonisation with extended-spectrum cephalosporin-resistant Enterobacteriaceae in different populations in Switzerland: prevalence, risk factors and molecular features.

Pires J, Kuenzli E, Hauser C, Tinguely R, Kasraian S, Atkinson A, Rauch A, Furrer H, Perreten V, Marschall J, Hatz C, Endimiani A.

J Glob Antimicrob Resist. 2018 Mar;12:17-19. doi: 10.1016/j.jgar.2017.11.007. Epub 2017 Nov 21. No abstract available.

PMID:
29175015
16.

Long-term Immune Response to Yellow Fever Vaccination in Human Immunodeficiency Virus (HIV)-Infected Individuals Depends on HIV RNA Suppression Status: Implications for Vaccination Schedule.

Veit O, Domingo C, Niedrig M, Staehelin C, Sonderegger B, Héquet D, Stoeckle M, Calmy A, Schiffer V, Bernasconi E, Flury D, Hatz C, Zwahlen M, Furrer H; Swiss HIV Cohort Study .

Clin Infect Dis. 2018 Mar 19;66(7):1099-1108. doi: 10.1093/cid/cix960.

PMID:
29140432
17.

European AIDS Clinical Society Second Standard of Care Meeting, Brussels 16-17 November 2016: a summary.

De Wit S, Battegay M, D'Arminio Monforte A, Lundgren JD, Oprea C, Antinori A, Bhagani S, Fätkenheuer G, Friis-Moller N, Furrer H, Mussini C; European AIDS Clinical Society.

HIV Med. 2018 Feb;19(2):77-80. doi: 10.1111/hiv.12559. Epub 2017 Oct 27.

PMID:
29076235
18.

Management of MDR-TB in HIV co-infected patients in Eastern Europe: Results from the TB:HIV study.

Efsen AMW, Schultze A, Miller RF, Panteleev A, Skrahin A, Podlekareva DN, Miro JM, Girardi E, Furrer H, Losso MH, Toibaro J, Caylà JA, Mocroft A, Lundgren JD, Post FA, Kirk O; TB: HIV study in EuroCoord.

J Infect. 2018 Jan;76(1):44-54. doi: 10.1016/j.jinf.2017.10.007. Epub 2017 Oct 20.

19.

Heterochronic evolution explains novel body shape in a Triassic coelacanth from Switzerland.

Cavin L, Mennecart B, Obrist C, Costeur L, Furrer H.

Sci Rep. 2017 Oct 20;7(1):13695. doi: 10.1038/s41598-017-13796-0.

20.

Assessing the danger of self-sustained HIV epidemics in heterosexuals by population based phylogenetic cluster analysis.

Turk T, Bachmann N, Kadelka C, Böni J, Yerly S, Aubert V, Klimkait T, Battegay M, Bernasconi E, Calmy A, Cavassini M, Furrer H, Hoffmann M, Günthard HF, Kouyos RD; Swiss HIV Cohort Study, Aubert V, Battegay M, Bernasconi E, Böni J, Braun DL, Bucher HC, Calmy A, Cavassini M, Ciuffi A, Dollenmaier G, Egger M, Elzi L, Fehr J, Fellay J, Furrer H, Fux CA, Günthard HF, Haerry D, Hasse B, Hirsch HH, Hoffmann M, Hösli I, Kahlert C, Kaiser L, Keiser O, Klimkait T, Kouyos RD, Kovari H, Ledergerber B, Martinetti G, Martinez de Tejada B, Marzolini C, Metzner KJ, Müller N, Nicca D, Pantaleo G, Paioni P, Rauch A, Rudin C, Scherrer AU, Schmid P, Speck R, Stöckle M, Tarr P, Trkola A, Vernazza P, Wandeler G, Weber R, Yerly S.

Elife. 2017 Sep 12;6. pii: e28721. doi: 10.7554/eLife.28721.

21.

Awareness and management of elevated blood pressure among human immunodeficiency virus-infected adults receiving antiretroviral therapy in urban Zambia: a call to action.

Bauer S, Wa Mwanza M, Chilengi R, Holmes CB, Zyambo Z, Furrer H, Egger M, Wandeler G, Vinikoor MJ.

Glob Health Action. 2017;10(1):1359923. doi: 10.1080/16549716.2017.1359923.

22.

First two cases of severe multifocal infections caused by Klebsiella pneumoniae in Switzerland: characterization of an atypical non-K1/K2-serotype strain causing liver abscess and endocarditis.

Babouee Flury B, Donà V, Buetti N, Furrer H, Endimiani A.

J Glob Antimicrob Resist. 2017 Sep;10:165-170. doi: 10.1016/j.jgar.2017.04.006. Epub 2017 Jul 17.

PMID:
28729207
23.

A decade of HIV care in rural Tanzania: Trends in clinical outcomes and impact of clinic optimisation in an open, prospective cohort.

Vanobberghen F, Letang E, Gamell A, Mnzava DK, Faini D, Luwanda LB, Mapesi H, Mwamelo K, Sikalengo G, Tanner M, Hatz C, Furrer H, Battegay M, Glass TR; KIULARCO Study Group.

PLoS One. 2017 Jul 18;12(7):e0180983. doi: 10.1371/journal.pone.0180983. eCollection 2017.

24.

Cohort profile: The Kilombero and Ulanga Antiretroviral Cohort (KIULARCO) - A prospective HIV cohort in rural Tanzania.

Letang E, Kalinjuma AV, Glass TR, Gamell A, Mapesi H, Sikalengo GR, Luwanda LB, Mnzava D, Ntamatungiro AJ, Ndaki R, Francis G, Vanobberghen F, Furrer H, Klimkait T, Felger I, Tanner M, Hatz C, Weisser M, Battegay M, Kiularco Study Group.

Swiss Med Wkly. 2017 Jul 4;147:w14485. doi: 10.4414/smw.2017.14485. eCollection 2017.

25.

Adverse events of raltegravir and dolutegravir.

Elzi L, Erb S, Furrer H, Cavassini M, Calmy A, Vernazza P, Günthard H, Bernasconi E, Battegay M; Swiss HIV Cohort Study Group.

AIDS. 2017 Aug 24;31(13):1853-1858. doi: 10.1097/QAD.0000000000001590.

26.

HIV viral load as an independent risk factor for tuberculosis in South Africa: collaborative analysis of cohort studies.

Fenner L, Atkinson A, Boulle A, Fox MP, Prozesky H, Zürcher K, Ballif M, Furrer H, Zwahlen M, Davies MA, Egger M; International Epidemiology Database to Evaluate AIDS in Southern Africa (IeDEA-SA).

J Int AIDS Soc. 2017 Jun 23;20(1):21327. doi: 10.7448/IAS.20.1.21327.

27.

Impact of early versus deferred antiretroviral therapy on estimated glomerular filtration rate in HIV-positive individuals in the START trial.

Achhra AC, Mocroft A, Ross M, Ryom-Nielson L, Avihingsanon A, Bakowska E, Belloso W, Clarke A, Furrer H, Lucas GM, Ristola M, Rassool M, Ross J, Somboonwit C, Sharma S, Wyatt C.

Int J Antimicrob Agents. 2017 Sep;50(3):453-460. doi: 10.1016/j.ijantimicag.2017.04.021. Epub 2017 Jun 28.

28.

A new, exceptionally preserved juvenile specimen of Eusaurosphargis dalsassoi (Diapsida) and implications for Mesozoic marine diapsid phylogeny.

Scheyer TM, Neenan JM, Bodogan T, Furrer H, Obrist C, Plamondon M.

Sci Rep. 2017 Jun 30;7(1):4406. doi: 10.1038/s41598-017-04514-x.

29.

Erratum to 'Intestinal colonisation with extended-spectrum cephalosporin- and colistin-resistant Enterobacteriaceae in HIV-positive individuals in Switzerland: molecular features and risk factors' [International Journal of Antimicrobial Agents 49/4 (2017) 519-521].

Pires J, Bernasconi OJ, Hauser C, Tinguely R, Atkinson A, Perreten V, Dona V, Rauch A, Furrer H, Endimiani A.

Int J Antimicrob Agents. 2017 Aug;50(2):276. doi: 10.1016/j.ijantimicag.2017.05.002. Epub 2017 Jun 5. No abstract available.

PMID:
28595854
30.

Comparison of dynamic monitoring strategies based on CD4 cell counts in virally suppressed, HIV-positive individuals on combination antiretroviral therapy in high-income countries: a prospective, observational study.

Caniglia EC, Cain LE, Sabin CA, Robins JM, Logan R, Abgrall S, Mugavero MJ, Hernández-Díaz S, Meyer L, Seng R, Drozd DR, Seage GR 3rd, Bonnet F, Dabis F, Moore RD, Reiss P, van Sighem A, Mathews WC, Del Amo J, Moreno S, Deeks SG, Muga R, Boswell SL, Ferrer E, Eron JJ, Napravnik S, Jose S, Phillips A, Justice AC, Tate JP, Gill J, Pacheco A, Veloso VG, Bucher HC, Egger M, Furrer H, Porter K, Touloumi G, Crane H, Miro JM, Sterne JA, Costagliola D, Saag M, Hernán MA; HIV-CAUSAL Collaboration; Centers for AIDS Research Network of Integrated Clinical Systems.

Lancet HIV. 2017 Jun;4(6):e251-e259. doi: 10.1016/S2352-3018(17)30043-7. Epub 2017 Apr 11.

31.

Strengthening HIV therapy and care in rural Tanzania affects rates of viral suppression.

Ntamatungiro AJ, Muri L, Glass TR, Erb S, Battegay M, Furrer H, Hatz C, Tanner M, Felger I, Klimkait T, Letang E; KIULARCO Study Group.

J Antimicrob Chemother. 2017 Jul 1;72(7):2069-2074. doi: 10.1093/jac/dkx095.

PMID:
28387865
32.

Mining for pairs: shared clinic visit dates identify steady HIV-positive partnerships.

Marzel A, Shilaih M, Turk T, Campbell NK, Yang WL, Böni J, Yerly S, Klimkait T, Aubert V, Furrer H, Calmy A, Battegay M, Cavassini M, Bernasconi E, Schmid P, Metzner KJ, Günthard HF, Kouyos RD; Swiss HIV Cohort Study (SHCS).

HIV Med. 2017 Oct;18(9):667-676. doi: 10.1111/hiv.12507. Epub 2017 Apr 4.

PMID:
28378387
33.

Incidence and risk factors for hypertension among HIV patients in rural Tanzania - A prospective cohort study.

Rodríguez-Arbolí E, Mwamelo K, Kalinjuma AV, Furrer H, Hatz C, Tanner M, Battegay M, Letang E; KIULARCO Study Group.

PLoS One. 2017 Mar 8;12(3):e0172089. doi: 10.1371/journal.pone.0172089. eCollection 2017.

34.

Intestinal colonisation with extended-spectrum cephalosporin- and colistin-resistant Enterobacteriaceae in HIV-positive individuals in Switzerland: molecular features and risk factors.

Pires J, Bernasconi OJ, Hauser C, Tinguely R, Atkinson A, Perreten V, Donà V, Rauch A, Furrer H, Endimiani A.

Int J Antimicrob Agents. 2017 Apr;49(4):519-521. doi: 10.1016/j.ijantimicag.2017.02.004. Epub 2017 Feb 27. No abstract available. Erratum in: Int J Antimicrob Agents. 2017 Aug;50(2):276.

PMID:
28254374
35.

Ethnicity predicts viral rebound after travel to the tropics in HIV-infected travelers to the tropics in the Swiss HIV Cohort Study.

Gebreselassie HM, Kraus D, Fux CA, Haubitz S, Scherrer A, Hatz C, Veit O, Stoeckle M, Fehr J, de Lucia S, Cavassini M, Bernasconi E, Schmid P, Furrer H, Staehelin C; Swiss HIV Cohort Study (SHCS).

HIV Med. 2017 Sep;18(8):564-572. doi: 10.1111/hiv.12491. Epub 2017 Mar 1.

PMID:
28247589
36.

Update of the Swiss guidelines on post-treatment Lyme disease syndrome.

Nemeth J, Bernasconi E, Heininger U, Abbas M, Nadal D, Strahm C, Erb S, Zimmerli S, Furrer H, Delaloye J, Kuntzer T, Altpeter E, Sturzenegger M, Weber R, For The Swiss Society For Infectious Diseases And The Swiss Society For Neurology.

Swiss Med Wkly. 2016 Dec 5;146:w14353. doi: 10.4414/smw.2016.14353. eCollection 2016. Review.

37.

Update of the Swiss guidelines on post-treatment Lyme disease syndrome.

Nemeth J, Bernasconi E, Heininger U, Abbas M, Nadal D, Strahm C, Erb S, Zimmerli S, Furrer H, Delaloye J, Kuntzer T, Altpeter E, Sturzenegger M, Weber R, For The Swiss Society For Infectious Diseases And The Swiss Society For Neurology.

Swiss Med Wkly. 2016 Dec 5;146:w14353. doi: 10.4414/smw.2016.14353. eCollection 2016 Dec 5. No abstract available.

38.

Cohort Profile: Collaboration of Observational HIV Epidemiological Research Europe (COHERE) in EuroCoord.

Chêne G, Phillips A, Costagliola D, Sterne JAC, Furrer H, Del Amo J, Mocroft A, d'Arminio Monforte A, Dabis F, Miro JM, Barger D, Termote M, Schwimmer C, Salbøl Brandt R, Friis-Moller N, Raben D, Haerry D, Egger M, Weller I, De Wit S.

Int J Epidemiol. 2017 Jun 1;46(3):797-797n. doi: 10.1093/ije/dyw211. No abstract available.

39.

Life expectancy in HIV-positive persons in Switzerland: matched comparison with general population.

Gueler A, Moser A, Calmy A, Günthard HF, Bernasconi E, Furrer H, Fux CA, Battegay M, Cavassini M, Vernazza P, Zwahlen M, Egger M; Swiss HIV Cohort Study, Swiss National Cohort.

AIDS. 2017 Jan 28;31(3):427-436. doi: 10.1097/QAD.0000000000001335.

40.

Clinical Course, Radiological Manifestations, and Outcome of Pneumocystis jirovecii Pneumonia in HIV Patients and Renal Transplant Recipients.

Ebner L, Walti LN, Rauch A, Furrer H, Cusini A, Meyer AM, Weiler S, Huynh-Do U, Heverhagen J, Arampatzis S, Christe A.

PLoS One. 2016 Nov 8;11(11):e0164320. doi: 10.1371/journal.pone.0164320. eCollection 2016.

41.

CD4/CD8 ratio and CD8 counts predict CD4 response in HIV-1-infected drug naive and in patients on cART.

Sauter R, Huang R, Ledergerber B, Battegay M, Bernasconi E, Cavassini M, Furrer H, Hoffmann M, Rougemont M, Günthard HF, Held L; and the Swiss HIV cohort study.

Medicine (Baltimore). 2016 Oct;95(42):e5094.

42.

Hepatitis C virus transmission among human immunodeficiency virus-infected men who have sex with men: Modeling the effect of behavioral and treatment interventions.

Salazar-Vizcaya L, Kouyos RD, Zahnd C, Wandeler G, Battegay M, Darling KE, Bernasconi E, Calmy A, Vernazza P, Furrer H, Egger M, Keiser O, Rauch A; Swiss HIV Cohort Study.

Hepatology. 2016 Dec;64(6):1856-1869. doi: 10.1002/hep.28769. Epub 2016 Oct 19.

43.

Hepatitis delta-associated mortality in HIV/HBV-coinfected patients.

Béguelin C, Moradpour D, Sahli R, Suter-Riniker F, Lüthi A, Cavassini M, Günthard HF, Battegay M, Bernasconi E, Schmid P, Calmy A, Braun DL, Furrer H, Rauch A, Wandeler G; Swiss HIV Cohort Study.

J Hepatol. 2017 Feb;66(2):297-303. doi: 10.1016/j.jhep.2016.10.007. Epub 2016 Oct 14.

PMID:
27746337
44.

Prevalence and Outcomes of Hepatitis B Coinfection and Associated Liver Disease Among Antiretroviral Therapy-Naive Individuals in a Rural Tanzanian Human Immunodeficiency Virus Cohort.

Ramírez-Mena A, Glass TR, Winter A, Kimera N, Ntamatungiro A, Hatz C, Tanner M, Battegay M, Furrer H, Wandeler G, Letang E.

Open Forum Infect Dis. 2016 Jul 29;3(3):ofw162. eCollection 2016 Sep.

45.

Development of HIV drug resistance and therapeutic failure in children and adolescents in rural Tanzania: an emerging public health concern.

Muri L, Gamell A, Ntamatungiro AJ, Glass TR, Luwanda LB, Battegay M, Furrer H, Hatz C, Tanner M, Felger I, Klimkait T, Letang E; KIULARCO Study Group.

AIDS. 2017 Jan 2;31(1):61-70.

46.

Opportunistic Diseases During HIV Infection-Things Aren't What They Used to Be, or Are They?

Furrer H.

J Infect Dis. 2016 Sep 15;214(6):830-1. doi: 10.1093/infdis/jiw086. Epub 2016 Apr 18. No abstract available.

PMID:
27559121
47.

New holostean fishes (Actinopterygii: Neopterygii) from the Middle Triassic of the Monte San Giorgio (Canton Ticino, Switzerland).

López-Arbarello A, Bürgin T, Furrer H, Stockar R.

PeerJ. 2016 Jul 19;4:e2234. doi: 10.7717/peerj.2234. eCollection 2016.

48.

Late presentation to HIV care despite good access to health services: current epidemiological trends and how to do better.

Darling KE, Hachfeld A, Cavassini M, Kirk O, Furrer H, Wandeler G.

Swiss Med Wkly. 2016 Aug 21;146:w14348. doi: 10.4414/smw.2016.14348. eCollection 2016. Review.

49.

Polyclonal Intestinal Colonization with Extended-Spectrum Cephalosporin-Resistant Enterobacteriaceae upon Traveling to India.

Pires J, Kuenzli E, Kasraian S, Tinguely R, Furrer H, Hilty M, Hatz C, Endimiani A.

Front Microbiol. 2016 Jul 12;7:1069. doi: 10.3389/fmicb.2016.01069. eCollection 2016.

50.

Dynamic models for estimating the effect of HAART on CD4 in observational studies: Application to the Aquitaine Cohort and the Swiss HIV Cohort Study.

Prague M, Commenges D, Gran JM, Ledergerber B, Young J, Furrer H, Thiébaut R.

Biometrics. 2017 Mar;73(1):294-304. doi: 10.1111/biom.12564. Epub 2016 Jul 26.

Supplemental Content

Loading ...
Support Center